All patients were required to give written informed consent
To have received a previous treatment with anthracyclines and taxanes
Previous radiotherapy is allowed, whenever the radiated area is not the only disease location
At least 4 weeks since the last previous antineoplastic treatment
Patients must have recovered from all previous toxicities
Karnofsky Performance status \>= 70%
Adequate hematological, renal, cardiac and hepatic function
Life expectancy of at least 12 weeks
Patients able to comply and to receive an adequate follow-up
You may not be if
Only bone metastases
Active infection
Previous treatment with one of the study drugs
Application of other cytotoxic chemotherapy
Insufficient renal function (creatinine clearance \< 60ml/min)
Clinically unstable brain metastasis
Pregnancy or lactation
Other primary malignancies (other than carcinoma-in-situ of the cervix or adequately treated basal cell cancer of the skin)
Abnormal liver function (bilirubin \> 2.0-fold upper normal limit (UNL); Alanine aminotransferase and aspartate aminotransferase \>2.5-fold UNL). In patients with hepatic metastasis, a value of Alanine aminotransferase and aspartate aminotransferase of up to 5-fold UNL is permitted
Males
Second malignancy (except for cervix carcinoma in situ or skin carcinoma - no melanoma- with an adequate treatment). Previous malignancies are allowed if disease-free survival is superior to 5 years, except for renal carcinoma or melanoma
